…more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

…THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) – AMSTERDAM, THE NETHERLANDS, OCTOBER 19-22, 2011 – The TEMSO phase III trial reported that oral teriflunomide 7 mg or 14 mg significantly reduced the annualized relapse rate compared to placebo (0.37 for either dose vs. 0.57; relative risk reduction 31%) (O’Connor et al. N Engl J Med 2011; 365: 1293-1303). Subscribe to read more It takes 30 seconds or login using y…

…CH IN MULTIPLE SCLEROSIS (ECTRIMS) – AMSTERDAM, THE NETHERLANDS, OCTOBER 19-22, 2011 – MS patients receiving a disease-modifying therapy (DMT) typically stop treatment or switch medications within a few years of starting treatment, according to a new database analysis of MS patients in British Columbia, Canada (Evans et al. ECTRIMS 2011; abstract P687). Subscribe to read more It takes 30 seconds or login using your email address Please enter the e…

REPORT FROM THE 25TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) – AMSTERDAM, THE NETHERLANDS, OCTOBER 19-22, 2011 – Two studies targeting B cells report mixed results – one positive, the other negative – in the treatment of MS, suggesting that there may be hidden challenges for this novel therapeutic approach. Subscribe to read more It takes 30 seconds or login using your email address Please ent…

REPORT FROM THE 25TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) – AMSTERDAM, THE NETHERLANDS, OCTOBER 19-22, 2011 – An Internet survey of MS patients reports that as patients worsen, they are increasingly likely to turn to the Internet rather than their neurologist for MS information (Miller et al. ECTRIMS 2011; abstract P178). Subscribe to read more It takes 30 seconds or login using your email…